In our Year in Review, we reflect on 2024. It’s been an excellent year in which we’ve seen growth across all areas of the business as the global radiology community looks to our unique application of autonomous AI to address the growing workload burden and scarcity of resources. Read on for some of the highlights.
Expanding the company to meet growing demand
Highly-regarded senior health tech executive Peter Corscadden became CEO in June, succeeding Gediminas Pekšys, who remains Head of AI. Peter’s appointment was part of a broader expansion of our team, driven by growing demand for our services.
This year also saw Donovan Bethanie join as Deployment Manager, Kristian Tusch as Senior Sales Manager, Ludovic Dome as Partnerships Manager, and Milda Shams as Senior Marketing Manager. In the autumn, we welcomed Tautvydas Petkus as a Software Engineer. Welcome all!
We’ve needed to grow our team in response to burgeoning demand. In 2024, our solutions analysed more than 1.5 million cases – almost three times the amount processed in 2023. The year ahead looks promising too.
Delivering evidence to show our effectiveness
We remain committed to credibility, innovation, and trustworthiness through continuous research.
Major 2024 findings include:
- A study with a major UK hospital shows that ChestLink brings great accuracy in identifying normal (clinically-insignificant) chest X-rays and can reduce reporting workload. Results suggest ChestLink can report approximately one quarter of normal studies autonomously.
- The Oxipit ChestEye algorithm was included in a study exploring the use of AI solutions for radiograph lung nodule detection and bone age prediction.
- A study into Oxipit Quality for AI-assisted double reading and featuring our CMO Naglis Ramanauskas showed clinically relevant missed findings in only 0.1% of chest radiographs following report authorisation.
Additionally, Signify Research published the landmark white paper Autonomous AI: Going Beyond CAD Image Analysis. This document outlines the pressing need for autonomous AI to help address the intensifying workforce shortages and increasing demand – a need that increasing numbers of people are asking us about.
Expanding our connections across the global radiology community
Oxipit continues to strengthen and expand its global partnerships, collaborating with leading healthcare technology organisations such as DeepC, Sectra, Blackford, HCK, and CARPL.
Our AI-driven solutions are deployed across Europe, South America, Africa, Australia, and North America, supporting a wide range of initiatives, from clinical deployments to retrospective studies. As healthcare systems face mounting diagnostic demands, the value of autonomous AI has never been clearer. Oxipit’s real-world applications address both immediate operational needs and long-term healthcare challenges, driving better efficiency and patient outcomes.
In 2024, Oxipit met the vibrant radiology community in industry-leading events across the globe. We attended the European Congress of Radiology (ECR), the UK Imaging and Oncology Congress (UKIO), Sectra’s UK meeting, Royal Australian and New Zealand College of Radiologists (RANZCR) ASM, Radiological Society of North America (RSNA) 2024, and the European Society of Thoracic Imaging (ESTI) Winter Course. Our autonomous radiology AI solution, ChestLink, generated significant interest in all of these events!
Looking forward to 2025
Peter Corscadden reflects on an exceptionally busy year for Oxipit:
We’ve seen that the global radiology community, facing resource scarcity and rising demand, is eager to do more with less and that our solutions can help. ChestLink demonstrates the value that autonomous AI can bring, with greater efficiency and high standards of diagnostic precision. Solutions like ChestEye and Quality continue to show how they do the same at the right stage of clinical workflow.
So while 2025 will bring challenges, we’re looking forward to working with customers and partners across the globe to deliver more solutions that release radiologist capacity and support exceptional care.